Psych Vivas · Addiction psychiatry — public health and systems
Harm reduction — structured clinical viva
Fellowship viva integrating post-overdose care, THN, NSP, OAT re-engagement, HCV, and anti-stigma communication.
On this page & tools
Target exams
Interpretation
Reveal interpretation
This is a post-overdose systems and ethics viva, not a simple detox request. She has just survived a life-threatening opioid overdose; partner-administered naloxone was appropriate first aid. She is now in withdrawal — a high-craving, high-relapse state — and has lost OAT continuity, a period when mortality risk rises (Sordo). Framing sterile equipment or naloxone as “enabling” misreads the evidence: take-home naloxone programmes reduce overdose mortality, and NSP associates with reduced HIV transmission.[1][2][3]
Acute priorities. Medical observation for re-sedation (especially if long-acting opioids or fentanyl possible); manage withdrawal supportively; offer same-episode restart of OAT (buprenorphine if adequate withdrawal and local protocol allow; or methadone re-induction low and slow — not automatic return to a prior high dose after gap); supply take-home naloxone and train her and her partner; facilitate NSP access; arrange HCV RNA and antiviral pathway; assess stimulant co-use, suicide risk, housing, children/safeguarding.[1][2][5]
Detox only. A short detox without maintenance and without overdose prevention is not the safer moral high ground when tolerance is falling — counsel mortality data and shared decision-making.[2]
Staff stigma conversation. Use Volkow’s framing: stigma delays care and increases the toll of addiction. Person-first language; reject “dirty urine” culture; explain that retaining people in care is the clinical goal. Hawk: accountability without termination.[4][5]
Key points
[1] [2] [3] [4]References
- [1]McDonald R, Strang J Are take-home naloxone programmes effective? Addiction, 2016.PMID 27028542
- [2]Sordo L, et al. Mortality risk during and after opioid substitution treatment BMJ, 2017.PMID 28446428
- [3]Aspinall EJ, et al. Needle and syringe programmes and HIV transmission Int J Epidemiol, 2014.PMID 24374889
- [4]Volkow ND Stigma and the Toll of Addiction N Engl J Med, 2020.PMID 32242351
- [5]Hawk M, et al. Harm reduction principles for healthcare settings Harm Reduct J, 2017.PMID 29065896